1. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London: European Medicines Agency; 2006.
2. IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European markets Parsippany: (IMS)-Institute for Healthcare Informatics. 2014.
https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf
. Accessed 30 Aug 2007.
3. Mckinsey and Company. Generating value in generics: finding the next five years of growth. Insights into Pharmaceuticals and Medical Product. Mckinsey and Company. 2013.
http://www.pharmatalents.es/assets/files/generating_value.pdf
. Accessed 30 Aug 2017.
4. Declerck PJ, Simoens S. European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33–40.
5. Health and Social Care Information Centre (HSCIC). Hospital prescribing England 2013–14. London: HSCIC. 2014.
http://content.digital.nhs.uk/catalogue/PUB15883/hosp-pres-eng-201314-rep.pdf
. Accessed 30 Aug 2017.